SELLAS Life Sciences (SLS) Equity Average (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Equity Average for 9 consecutive years, with $9.4 million as the latest value for Q3 2024.
- On a quarterly basis, Equity Average rose 1750.89% to $9.4 million in Q3 2024 year-over-year; TTM through Sep 2024 was $9.4 million, a 1750.89% increase, with the full-year FY2023 number at -$1.6 million, down 112.4% from a year prior.
- Equity Average was $9.4 million for Q3 2024 at SELLAS Life Sciences, up from $6.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $31.1 million in Q2 2021 to a low of -$5.9 million in Q4 2023.
- A 5-year average of $12.0 million and a median of $9.0 million in 2023 define the central range for Equity Average.
- Peak YoY movement for Equity Average: tumbled 167.65% in 2023, then skyrocketed 1750.89% in 2024.
- SELLAS Life Sciences' Equity Average stood at $18.0 million in 2020, then skyrocketed by 30.76% to $23.5 million in 2021, then tumbled by 62.84% to $8.7 million in 2022, then crashed by 167.65% to -$5.9 million in 2023, then soared by 259.32% to $9.4 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Equity Average are $9.4 million (Q3 2024), $6.3 million (Q2 2024), and $854000.0 (Q1 2024).